Brennan Daniel J.

Brennan Daniel J., the EVP and CFO of Boston Scientific (BSX), has been a consistent seller of company stock over the past year, with his Form 4 filings revealing a clear disposition bias. Across 57 total transactions spanning three companies, Brennan has executed zero open-market purchases and zero acquisitions, while selling approximately $20.7 million worth of shares. The overwhelming majority of this activity occurred in BSX, where he completed a series of open-market sales in February 2025, including a $7.09 million sale on February 19 and additional sales of $1.53 million and $301,818 on February 18. These sales were accompanied by routine option exercises (coded "M") and share withholdings for tax purposes (coded "F"), which are mechanical transactions rather than discretionary trades. The recent pattern in Brennan's filings shows a shift away from BSX toward two other companies where he holds positions: Madrigal Pharmaceuticals (MDGL) and Waters Corporation (WAT). His most recent transactions, dated June 17, 2026, for MDGL and February 25, 2026, for WAT, are all coded "A" (grants or awards), which represent compensation rather than purchases. These awards carry zero dollar values, indicating they are equity grants tied to his board or executive roles rather than market transactions. Notably, Brennan has not executed a single open-market sale in either MDGL or WAT, suggesting his selling activity is concentrated exclusively in BSX. The data reveals a stark asymmetry: Brennan's only discretionary market activity is selling, and it is entirely focused on BSX, where he sold roughly $8.9 million in open-market transactions during February 2025. His recent filings for MDGL and WAT contain only compensatory awards, with no buying or selling. This pattern—heavy selling in one company followed by a period of purely compensatory activity in others—indicates a deliberate reduction of his BSX stake while maintaining passive positions elsewhere. The absence of any "P" (purchase) codes across all 57 transactions underscores that Brennan has not added to any of his positions through the open market during this period.